Literature DB >> 15819294

Laparoscopic biopsy and ureterolysis in Erdheim-Chester disease.

Erik P Castle1, Mitchell R Humphreys, Paul E Andrews.   

Abstract

Erdheim-Chester disease (ECD) is a rare, progressive, non-Langerhans cell histiocytosis that portends a poor prognosis. Misdiagnosis is common until adequate tissue analysis reveals the infiltrative histiocytic process. The disease process affects various organ systems, and effective treatment options are limited. Knowledge of the constellation of signs and symptoms associated with ECD is important to avoid misdiagnosis. We describe a patient who underwent laparoscopic bilateral ureterolysis and laparoscopic biopsy for presumed retroperitoneal fibrosis confirmed previously by percutaneous needle biopsy findings. The final pathologic diagnosis based on laparoscopic biopsy results was ECD. As evidenced by this case, ureterolysis offers little benefit to patients with ECD.

Entities:  

Mesh:

Year:  2005        PMID: 15819294     DOI: 10.4065/80.4.546

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation.

Authors:  Moozhan Nikpanah; Lauren Kim; S Mojdeh Mirmomen; Rolf Symons; Ioannis Papageorgiou; William A Gahl; Kevin O'Brien; Juvianee I Estrada-Veras; Ashkan A Malayeri
Journal:  Eur Radiol       Date:  2018-03-19       Impact factor: 5.315

2.  Erdheim-Chester Disease With Renal Involvement: A Case Report.

Authors:  Ali Kürşat Ganiyusufoğlu; Gökşen Gökşenoğlu; Burçin Tunç; Nurdan Paker
Journal:  Arch Rheumatol       Date:  2017-02-01       Impact factor: 1.472

Review 3.  Robot-assisted laparoscopic ureterolysis: case report and literature review of the minimally invasive surgical approach.

Authors:  Stéfanie A Seixas-Mikelus; Susan J Marshall; D Dawon Stephens; Aaron Blumenfeld; Eric D Arnone; Khurshid A Guru
Journal:  JSLS       Date:  2010 Apr-Jun       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.